Global $525+ Million Ophthalmology Optical Coherence Tomography (OCT) Markets Analysis & Forecasts, 2016-2020 & 2021-2026
November 18, 2021 06:33 ET
|
Research and Markets
Dublin, Nov. 18, 2021 (GLOBE NEWSWIRE) -- The "Optical Coherence Tomography (OCT) for Ophthalmology - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's...
Ocutrx Technologies Leads the Field With Three Patents On Near-eye Pupil-forming Catadioptric Optical Engine
November 17, 2021 09:00 ET
|
Ocutrx Technologies, Inc
LAGUNA BEACH, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ocutrx Technologies, Inc. , (formerly Ocutrx Vision Technologies, LLC) an augmented/extended reality (AR/XR) and 3D visualization manufacturing...
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Eyenuk Announces Publication of Strong EyeArt® Pivotal Clinical Trial Results in JAMA Network Open
November 15, 2021 14:38 ET
|
Eyenuk, Inc.
LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...
Ziemer USA Announces Partnership With CorneaGen
November 11, 2021 09:00 ET
|
Ziemer USA, Inc.
ALTON, Ill., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Ziemer USA, Inc., a wholly owned subsidiary of Ziemer AG (Port, Switzerland), manufacturer and developer of FEMTO Laser Technology (FEMTO LDV Z8) and...
Clearside Biomedical to Participate in Upcoming Investor Events in November and December 2021
November 11, 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
ProQR to Webcast Virtual Analyst Event on November 18
November 11, 2021 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 16:05 ET
|
Clearside Biomedical, Inc.
- XIPERE™ is First FDA-Approved Product for Injection into the Suprachoroidal Space - - Approval-Related Milestones to Provide $19 Million in Non-Dilutive Funding - - Continued Progress in...
Clinical Trial Market Size & Share 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
November 09, 2021 06:00 ET
|
Graphical Research
Pune, India, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The global clinical trial market size is estimated to rise exponentially during the forecast period, as the need for advanced vaccines and drugs to...
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration
November 08, 2021 09:24 ET
|
Ocugen
MALVERN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...